FDA's Perspective on AI in Drug Development

According to Dr. Nicola Davies, artificial intelligence (AI) has quickly changed from a technology with potential to a key part of pharmaceutical innovation. AI is currently thought to create between $350 billion and $410 billion in value annually for pharmaceutical companies. The market is predicted to increase by 42.68%, which is about $15 billion, between 2024 and 2029. AI is notably shortening the drug discovery process from around five or six years to just one year.

This article is for registered users; please register to read it for free. A free trial offers access to exclusive content, interviews, summaries, and insights from experts in the pharmaceutical and biotechnology fields for one week. Registered users can log in. If your trial has ended, you can subscribe. Try a 7-day trial before subscribing, or subscribe for £77 per month.

The Pharma Letter
39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom